Ultragenyx Pharmaceutical
RARE
165 hedge funds and large institutions have $2.5B invested in Ultragenyx Pharmaceutical in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 70 increasing their positions, 39 reducing their positions, and 21 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 39
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
24% more capital invested
Capital invested by funds: $2.01B → $2.5B (+$489M)
1% more funds holding
Funds holding: 163 → 165 (+2)
2.89% less ownership
Funds ownership: 101.54% → 98.65% (-2.9%)
89% less call options, than puts
Call options by funds: $1.03M | Put options by funds: $9.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$58.5M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$46.8M |
| 3 |
ClearBridge Investments
New York
|
+$39.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.3M |
| 5 |
BlackRock
New York
|
+$25.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$13.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$12.8M |
| 3 |
Legal & General Group
London,
United Kingdom
|
-$6.64M |
| 4 |
PC
Pier Capital
Stamford,
Connecticut
|
-$5.83M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$4.41M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
176
Tower Research Capital (TRC)
New York
| – | -$47K | -1,011 | Closed |
|
|
EWM
177
Edge Wealth Management
New York
| – | -$13K | -300 | Closed |
|
|
MAM
178
Meeder Asset Management
Dublin,
Ohio
| – | -$3K | -74 | Closed |
|
179
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$2K | -51 | Closed |
|
|
STA
180
Summit Trail Advisors
New York
| – | -$1K | -16 | Closed |
|
181
AssetMark Inc
Concord,
California
| – | -$1K | -12 | Closed |
|
|
S
182
SignatureFD
Atlanta,
Georgia
| – | +$50 | +1 | New |
|
|
GWS
183
Glassman Wealth Services
Vienna,
Virginia
| – | +$302 | +6 | New |
|
RARE Hedge Fund Activity: Q1 2018 in Review
165 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2018, worth a combined $2.5B — up 24% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RARE positions and 21 closed out — a net gain of 7 holders — while 70 added to existing stakes and 39 trimmed.
The largest buyer was Ameriprise, adding an estimated $58.5M. The largest seller was Royal Bank of Canada, cutting an estimated $13.7M.
- 165 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2018, up from 163 in Q4 2017.
- Funds reported $2.5B of Ultragenyx Pharmaceutical stock for Q1 2018, up 24% quarter-over-quarter.
- 28 funds opened new Ultragenyx Pharmaceutical positions in Q1 2018 and 21 closed out, a net change of +7 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2018 was Ameriprise, an estimated $58.5M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2018 was Royal Bank of Canada, an estimated $13.7M sold.
Based on aggregated 13F filings for Q1 2018.